May 14, 2026
TempraMed Technologies Ltd.
ISIN: CA88024B1022
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets Highlights - Granted Patent covers the design of VIVI Cap Smart across major international,...
Read more >>TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights - Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture- Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics- Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium...
Read more >TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership. Vancouver, BC – December 10, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr....
Read more >TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI...
Read more >TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company...
Read more >TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
- Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction - Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance - One of many distribution...
Read more >TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
- Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz - Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more- Strategic agreement supports TempraMed’s global shift from online B2C to major pharmacy networks and B2B medical payors- Distribution to over 2,500 outlets including pharmacy chains, supermarkets,...
Read more >